Compare SAFE & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAFE | CRVS |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1999 | 2016 |
| Metric | SAFE | CRVS |
|---|---|---|
| Price | $16.56 | $14.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $19.00 | ★ $30.17 |
| AVG Volume (30 Days) | 352.1K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | 7.43 | ★ 48.04 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $385,552,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | $41.13 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $12.76 | $3.96 |
| 52 Week High | $17.16 | $26.95 |
| Indicator | SAFE | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 57.18 |
| Support Level | $14.71 | $14.24 |
| Resistance Level | N/A | $16.85 |
| Average True Range (ATR) | 0.45 | 0.81 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 73.76 | 56.33 |
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.